HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLTRF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$80.43M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
HLS Therapeutics Inc.HLS Therapeutics Inc.-12--13%2.60.8
$2.46

Current Fair Value

6.1% downside

Overvalued by 6.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$80.43 Million
Enterprise Value$109.96 Million
Earnings per Share$-0.4
Beta0.82
Outstanding Shares30,884,465

Return

Return on Equity-13.46%ROE
Return on Assets-5.67%
Return on Invested Capital-3.18%

Valuation & Multiples

P/E Ratio-12P/E Ratio
PEG27.18PEG
Price to Sales2.62Price to Sales
Price to Book Ratio2.62Price to Book Ratio
Enterprise Value to Revenue1.94
Enterprise Value to EBIT-36.91
Enterprise Value to Net Income-17
Total Debt to Enterprise0.37
Debt to Equity0.81Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$0.07
Est. -$0.07
Revenue
$14.15 M
Est. $14.87 M

Next Earnings Call

Expected Date
March 18, 2027
EPS Estimate
-$0.03
Consensus analyst estimate
Revenue Estimate
$16.30 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About HLS Therapeutics Inc.

85 employees
CEO: Craig Stuart Millian

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. I...